44 results about "CD5" patented technology

The invention discloses a kit and method for detecting leukemia and lymphoma based on full-spectrum flow cytometry, the kit comprises 25 antibodies, the antibodies are specifically bound with fluorescein respectively, and leukemia and lymphoma are detected through full-spectrum flow cytometry; the 25 kinds of antibodies comprise HLA-DR (human leukocyte antigen-DR), CD38, CD7, CD34, Lambda, CD19, CD64, CD14, CD5, CD123, CD16, CD20, Kappa, CD117, CD13, CD45, CD11b, CD2, CD10, CD8, CD15, CD4, CD3, CD56 and CD33. The kit comprehensively covers development stages of various lines of bone marrow cells, and common abnormal expressions of various leukemia, myelodysplastic syndromes and lymphoma, and can preliminarily screen various leukemia and lymphoma.

The invention relates to the technical field of biological medicine. The invention provides highly branched poly (beta-amino ester) and a preparation method thereof. The invention also provides lipid nanoparticles which contain the compound and are used for efficiently delivering mRNA, a preparation method of the lipid nanoparticles, and application of the lipid nanoparticles in preparation of CD5 antibody targeted nucleic acid drug delivery carriers. The highly branched poly (beta-amino ester) prepared by the scheme of the invention has better mRNA binding capacity and in-vivo stability, the obtained lipid nanoparticles have high transfection efficiency, and efficient transfection of specific tissues or cells can be better realized.

The invention relates to an antibody composition for detecting abnormal CTL (cytotoxic T lymphocyte) cells of hemophagocytic syndrome and application of the antibody composition, and the antibody composition comprises a CD2 antibody, a CD3 antibody, a CD4 antibody, a CD5 antibody, a CD7 antibody, a CD8 antibody, a CD56 antibody, a CD57 antibody, a Granzyme B antibody, a Perforin antibody, a TRBC1 antibody and a CD45 antibody. In the technical scheme provided by the invention, key phenotypic characteristics of CTL (Cytotoxic Lymphocyte) can be completely covered by various antibodies aiming at T cell and NK cell surface markers, T large granular lymphocyte markers, cytotoxic granular proteins, T cell receptor constant regions and leukocyte common antigens; wherein the clonality of the CTL cells is judged through the expression level of the TRBC1 antibody, and the cytotoxic function activity of the CTL cells is evaluated through the expression levels of Granzyme B and Perforin.

The application belongs to the technical field of biological medicine, and discloses a cyclic peptide molecule specifically targeting CD5 and purposes thereof. The surface receptor CD5 of immune cells (T cells, B cells) has been proved to be a potential tumor treatment target, the present application uses the phage display technology widely applied to the development of polypeptide or antibody drugs to carry out multiple rounds of in vitro screening on human CD5 protein, and obtains a cyclic peptide molecule with drug potential and capable of specifically combining with CD5 through second-generation sequencing. The cyclic peptide molecule contains two cysteines, is modified into a ring through a specific chemical crosslinking agent, and the affinity of the cyclic peptide molecule to CD5 is determined to be in the low micromolar level through surface plasmon resonance technology, thereby laying a foundation for the development of a CD5-targeting inhibitor.

The present invention relates to anti-CD5 nanobodies and their applications in in vivo CAR cell therapy. Specifically, the present invention provides 10 nanobodies targeting murine CD5, which have the functions of high affinity and high specific binding to CD5, can be recognized by CD5-positive cells (such as T cells) and internalized into cells, and can be used for specific targeting of T cells in mice. The nanobodies of the present invention can be conjugated with delivery vectors to prepare delivery vectors with immunocyte targeting properties for research and application in in vivo CAR therapy and the like.

The invention discloses an antibody composition for detecting mother cell plasma cell-like dendritic cells. The antibody composition comprises a first group of antibodies, a second group of antibodies, a third group of antibodies and a fourth group of antibodies, the first group of antibodies comprises a CD36 antibody, a CD4 antibody, a CD14 antibody, a CD56 antibody, a CD5 antibody, a CD3 antibody, a CD8 antibody, a CD2 antibody, a CD7 antibody and a CD45 antibody; the second group of antibodies comprises an HLA-DR (Human Leukocyte Antigen-DR) antibody, a CD33 antibody, a CD34 antibody, a CD56 antibody, a CD117 antibody, a CD123 antibody, a CD19 antibody, a CD38 antibody and a CD45 antibody; the third group of antibodies comprises a CD303 antibody, a CD304 antibody, a CD41 antibody, a CD56 antibody, a CD13 antibody, a CD85j antibody, a CD64 antibody, a CD15 antibody and a CD45 antibody; and the fourth group of antibodies comprises TdT, MPO, CD56, cCD3, CD10, cCD22 and CD45 antibodies. The antibody composition can be used for accurately detecting tumor abnormal BPDCN cells.

The present invention provides a pluripotent stem cell into which a nucleic acid encoding a chimeric antigen receptor (CAR) specific to CD5, CD2, or CD6 has been introduced. The present invention also provides a CAR-T cell specific to CD5, CD2, or CD6, which is obtained by inducing the differentiation of the pluripotent stem cell into a T cell, and has the following characteristics: (a) that the expression of CD5, CD2, and CD6 is reduced compared to that of a corresponding CAR-T cell derived from peripheral blood; and (b) that cytotoxic activity against T-cell tumors is higher than that of the corresponding CAR-T cell and a CD5, CD2, or CD6 gene-deficient CAR-T cell, which are derived from peripheral blood.

This embodiment provides cells containing heterologous nucleic acid molecules inserted at the CD5 gene locus. A composition containing such cells, as well as methods for producing and using such cells and compositions, are also provided herein.

The invention relates to the technical field of biological medicine, in particular to application of S100A9 protein to preparation of a product for predicting the recurrence risk of AML. The product is used for detecting a marker CD15, a marker CD33, a marker CD14, a marker CD15, a marker CD33, a marker CD64, a marker CD5, a marker CD14, a marker CD10, a marker CD19, a marker CD33, a marker CD34, a marker CD64, a marker CD117, a marker CD13 or a marker CD45. Therefore, the accuracy of predicting the AML recurrence risk is improved.

The invention discloses a method for detecting non-target cells in amniotic epithelial cells, which comprises reagents for detecting one or more of the following gene markers: FCGBP, RNASE6, DAB2, STAB1, RAB3IL1, CSF1R, CD68, CD209, EGFL7, LGALS2, LILRB4, HLA-DMB, HLADMA, CD74, ANPEP, CD44, CCR7, CD3G, CD3D, CD27, CD5, SPOCK2, TCF7, GZMH, KLRC2 and the like. Wherein the non-target cells are selected from macrophage-like cells, monocyte-like cells, T cell-like cells, NK cell-like cells, myeloid-like cells and neutrophil-like cells, a detection method is provided for quality control of the amniotic epithelial cells, and guidance is also provided for a cell product preparation process.

Monitoring active disease or progressive disease under therapy in chronic lymphocytic leukemia (CLL) represents a challenge to earlier and better adapt therapeutic strategy, notably in the era of targeted therapies in which minimal residual detection or mutations are sometimes not associated to poor clinical outcome. By following CLL patients before treatment (Binet stages A and B / C) or during targeted therapy, the Inventors developed a new flow cytometric method, based on CD69, CD49d, CD20 and CD279 expression at the surface of CD19+ / CD5+ B leukemic cells. Analyses of these markers alone or in combination show that CD69 / CD49d / CD20 / CD279 co-expression (quadruple population, QP) > 0.5% is the best criterion predicting CLL active disease or progression under therapy. This new flow cytometry immunophenotyping could help clinicians to monitor CLL evolution and quickly adapt their therapeutic strategy. Accordingly, the present invention relates to an ex vivo method for predicting active Chronic Lymphocytic Leukemia (CLL) or progressive CLL under therapy in a subject suffering from CLL, comprising the step of quantifying a population of CD69+ / CD49d+ / CD20+ / CD279+ cells in a sample obtained from the subject.

An antibody or antigen binding fragment that specifically binds to CD5, a polypeptide, a chimeric antigen receptor, an immune effector cell, a nucleic acid fragment, a vector, a host cell, a pharmaceutical composition, a preparation method, and use thereof in the treatment of diseases and in the detection of CD5, etc., which have important meanings for developing therapeutic drugs and CD5 detection reagents.

The present disclosure features polypeptides capable of binding to Cluster of Differentiation 5 (CD5) antigens and polynucleotides encoding the CD5 binding polypeptides, compositions comprising them, and methods of use thereof. The disclosure also features lipid nanoparticles comprising the CD5 binding polypeptides and methods of use thereof for delivering polynucleotides (e.g., polynucleotides encoding chimeric antigen receptors) to T cells in vivo.

The present disclosure provides delivery particles comprising: (a) a targeting moiety on the surface of the particle, wherein the targeting moiety comprises an antibody or an antigen-binding fragment thereof that binds to a T cell antigen selected from CD5, CD7, and CD27; and (b) a payload encapsidated within the particle. The disclosure provides methods of using the particles.

The invention relates to application of a CD2 / 5 / 7 knockout anti-CD2 / 5 / 7 chimeric antigen receptor T cell to T cell lymphoma and leukemia. The present invention includes compositions and methods for treating T cell lymphoma and leukemia. In certain aspects, the compositions and methods include CAR T cells that target CD2, CD5, or CD7 and modified cells in which CD2, CD5, or CD7 has been knocked out.

The application discloses a simple and low-cost method for culturing canine NK cells in vitro and belongs to the technical field of cell culture. The method comprises the following steps: separating NK cells from peripheral blood of a dog, culturing the NK cells with a canine NK cell activation culture medium for 24-48 hours, then continuing to culture the NK cells with a canine NK cell expansion culture medium, adding the canine NK cell expansion culture medium after 48 hours, expanding the cells in a bottle when the cells are obviously expanded, otherwise maintaining the cells in the original bottle after centrifugation, adding liquid and expanding the cells in a bottle or culturing the cells in the original bottle every other day, and harvesting the canine NK cells after 12-18 days. The method provided by the application does not need to activate the canine NK cells by using engineered trophoblast cells and multiple cell factors, and does not need to activate the cells by using an antibody, so that the method is simple and low in cost, and the cultured canine NK cells normally express NKp46, do not express CD3 and CD5, and have normal inhibitory and killing tumor abilities.

The invention provides application of a CD5-targeting reagent in the aspects of reducing the drug resistance of tumor cells and improving the anti-tumor curative effect of drugs, and clarifies for the first time that CD5 molecules can promote high expression and cell nucleus displacement of transcription factors FOXO3a and FOXO4 in a forkhead cassette O signal channel; therefore, expression increase of the ABC drug-resistant protein family in diffuse large B-cell lymphoma tumor cells is mediated, and drug resistance of tumor cells to various chemotherapeutic drugs is promoted. Further, it is found that the celecoxib can significantly inhibit expression of CD5 molecule mediated ABC drug-resistant protein in B-cell lymphoma cells, then the celecoxib and chemotherapeutic drugs are combined for application, the killing effect of traditional chemotherapeutic drugs on diffuse large B-cell lymphoma tumor cells is significantly enhanced, and the chemotherapeutic drug resistance of diffuse large B-cell lymphoma is overcome. The anti-drug-resistant tumor strategy can overcome the problems of low treatment response rate and poor prognosis of the CD5-positive diffuse large B-cell lymphoma to the existing chemotherapy regimen due to multidrug resistance, and significantly improves the anti-tumor treatment effect.

The invention belongs to the technical field of immunological detection, and discloses an antibody composition for detecting early precursor acute T-cell lymphocytes, which comprises a first group of antibodies, a second group of antibodies and a third group of antibodies, the first group of antibodies comprises a CD99 antibody, a CD4 antibody, a CD34 antibody, a CD56 antibody, a CD5 antibody, a CD3 antibody, a CD8 antibody, a CD2 antibody, a CD7 antibody and a CD45 antibody; the second group of antibodies comprises an HLA-DR (Human Leukocyte Antigen-DR) antibody, a CD33 antibody, a CD34 antibody, a CD117 antibody, a CD13 antibody, a CD11b antibody, a CD7 antibody, a CD64 antibody, a CD38 antibody and a CD45 antibody; the third group of antibodies comprises a TdT antibody, an MPO antibody, a CD10 antibody, a CD1a antibody, a cCD3 antibody, a CD7 antibody, a CD19 antibody, a cCD22 antibody and a CD45 antibody; each antibody is a monoclonal antibody marked with a detection marker. The antibody composition can be used for rapidly, accurately and comprehensively detecting early-stage precursor T cell acute lymphocytes at one time.

This invention discloses an anti-CD5 protein nanobody and its applications, relating to the field of nanobody biosynthesis technology. Utilizing a camel-derived nanobody library and targeting mouse CD5 protein, this invention employs phage display technology for in vitro enrichment and panning. Camel-derived nanobody sequences targeting CD5 protein are obtained through monoclonal high-throughput ELISA screening. These five nanobody sequences can be used to detect CD5 protein expression, for the diagnosis and screening of related tumors, and also for the preparation of drugs to treat related tumors.

This invention provides a method for screening peptides that specifically target T cells, comprising providing T cells having a subset selected from CD1, CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, CD150, CD152 (CTLA-4), CD153, CD154 (CD40L) The T cells are labeled with at least one of the following surface antigen markers: CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, LAG3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6, and CCR7. The T cells are then contacted with a peptide display library, and target peptides that specifically bind to the T cells are screened therefrom.

The invention discloses a simple and low-cost method for culturing canine NK cells in vitro, and belongs to the technical field of cell culture. The method comprises the following steps: separating NK cells from peripheral blood of a dog, culturing for 24-48 hours by using a dog NK cell activation culture medium, then continuously culturing by using a dog NK cell amplification culture medium, supplementing the dog NK cell amplification culture medium after 48 hours, expanding a bottle if the cells are obviously amplified, otherwise, maintaining original bottle culture after centrifuging, and subsequently supplementing liquid and expanding the bottle or performing original bottle culture every two days, and harvesting the canine NK cells after 12-18 days. According to the method provided by the invention, engineering trophoblasts and multicellular factors are not needed to activate the canine NK cells in the whole process, antibody coating activation is also not needed, the operation is simple and convenient, the cost is relatively low, and the cultured canine NK cells normally express NKp46, do not express CD3 and CD5 and have normal tumor inhibiting and killing capabilities.

This invention belongs to the field of biodetection technology, specifically relating to early warning biomarkers for Sjögren's syndrome and their applications. The biomarkers include plasma proteins selected from LGALS9, TNFRSF9, and CD5 proteins. The AUC value of this biomarker for early prediction of Sjögren's syndrome is 0.69.

Provided is a method for screening polypeptides that specifically target T cells, comprising: providing T cells having a surface antigen marker selected from at least one of CD1, CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, CD150, CD152 (CTLA-4), CD153, CD154 (CD40L), CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, LAG3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6, and CCR7; and contacting the T cells with a polypeptide display library, and screening therefrom target polypeptides that specifically bind to the T cells.

The application discloses a VSIG4 antibody and application thereof, and relates to the technical field of biological medicines. The antibody provided by the application can block VSIG4-CD5 interaction, thereby relieving tumor progression.

The present invention relates to a novel anti-CD5 chimeric antigen receptor and use thereof. The chimeric antigen receptor of the present invention can specifically bind to the extracellular membrane-proximal domain of CD5, and immune cells expressing the chimeric antigen receptor exhibit reduced reactivity with respect to normal cells expressing CD5, and thus the present invention can be used as an efficient therapeutic agent for various CD5-mediated cancer diseases.

The CD5 antigen (or "Differentiation Cluster 5") is a co-receptor of the antigen receptor present as a marker on the surface of T cells as well as a sub-population of B lymphocytes (i.e. B1a cell). There is a need for CD5 targeting antibodies with depleting and T-cell activation effects as well as CD5 targeting antibodies triggering AICD. The present invention fulfills the need by providing a new antibody (ACT02).

The present invention provides compositions and methods for treating T-cell lymphoma and T-cell leukemia. [Solution] A method for treating cancer comprising the steps of administering a first modified cell containing a chimeric antigen receptor (CAR) comprising an antigen-binding domain, a transmembrane domain, and an intracellular domain to the subject, and administering a second modified cell in which the endogenous CD5 gene is knocked out to the subject. Preferably, the antigen-binding domain is an antigen-binding domain that can bind to CD2, CD5, or CD7, and preferably the endogenous CD5 gene is knocked out by the CRISPER / Cas9 method.

The invention provides a CD5 / LNP-FAP CAR nanoparticle as well as a preparation method and application thereof, and relates to the technical field of biology. The CD5 / LNP-FAP CAR nanoparticle provided by the invention comprises a delivery carrier and FAP CAR mRNA (messenger Ribonucleic Acid) loaded on the delivery carrier, wherein the FAP CAR mRNA can express a chimeric antigen receptor taking a fibroblast activation protein (FAP) as a specific target spot. The CD5 / LNP-FAP CAR nanoparticle is good in stability and low in cost, delivery of nucleic acid to T cells and introduction of FAP CAR mRNA into the T cells can be effectively achieved, the recognition and killing ability of the T cells to over-activated fibroblasts can be improved, fibrotic diseases are treated by killing the over-activated fibroblasts, and the CD5 / LNP-FAP CAR nanoparticle can be used for preparing drugs for treating the fibrotic diseases.